Zogenix, Inc. (NASDAQ: ZGNX) is on The StockGuru Leader Board today. The stock is up as much as 17.75% on Monday.
Volume traded – so far – as this release was issued intraday: 1,212,132
Join in on the Discussion about ZGNX: http://members.stockguru.com/stocks/zgnx/
About the Company:
Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial products include Sumavel DosePro (sumatriptan injection) needle-free delivery System that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The companys lead product candidate, ZX002, is an oral, single-entity controlled-release formulation of hydrocodone under Phase III clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. markets and sells its Sumavel DosePro through field sales force primarily to neurologists and other key prescribers of migraine medications, including headache clinics and headache specialists in the United States. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.
About the StockGuru Leader Board:
We watch for stocks moving up and creating a positive momentum in the market. We are not compensated for coverage.
Feel free to suggest a stock for coverage if you see it breaking out. Contact: [email protected].
StockGuru.com
StockGuruCanada.com
Shareholdervision.com
BoldStocks.com
IR Affiliates – IRIR.co
StoneBridge Web & SEO – StonebridgeIQ.com
All content on StockGuru.com is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: [email protected] or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070